Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial evaluating Combining current day 1 and day 15 IV doses of BRIUMVI into one 600mg day 1 dose BRIUMVI

Next Previous
Trial Profile

A pivotal trial evaluating Combining current day 1 and day 15 IV doses of BRIUMVI into one 600mg day 1 dose BRIUMVI

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ublituximab (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use

Most Recent Events

  • 03 Nov 2025 According to TG Therapeutics, the company commenced patient enrollment into the Phase 3 pivotal program for subcutaneous ublituximab.
  • 03 Nov 2025 Status changed from planning to recruiting.
  • 07 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top